Murphy - Lian Laboratory
Program in Dermatopathology

previous arrow
next arrow


What is today the Program in Dermatopathology Skin Stem Cell and Epigenetics Laboratory was launched in 1982 at the Brigham and Women’s Hospital and quickly became the first NIH-funded dermatopathology facility at Harvard. Over the years and through its travels, it has grown to include investigative efforts that now impact on translational studies focused on melanoma & non-melanoma skin cancer prevention and therapy, psoriasis, atopic dermatitis, chronic ulcers & skin regeneration, and complications of bone marrow transplantation & targeted immunotherapies. Led by internationally recognized dermatopathologist and investigator, Dr. George F. Murphy, in association with Dr. Christine G. Lian, a leading dermatopathologist, immunologist and epigeneticist, and allied with the Harvard Stem Cell Institute Skin Program, the lab’s current and future vision is the development of team science approaches that address critical and as yet unanswered bench-to-bedside issues, thus leading to more effective and personalized strategies to benefit patients worldwide who suffer from various skin diseases.